Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
HighlightsCreative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
HighlightsCreative Biolabs has established a broad range of platforms for developing novel antibodies or equivalents. These cutting-edge technologies enable our scientists to meet your demands from different aspects and tailor the most appropriate solution that contributes to the success of your projects.
HighlightsWith deep understanding in antibody-related realms and extensive project experience, Creative Biolabs offers a variety of references to help you learn more about our capacities and achievements, including infographic, flyer, case study, peer-reviewed publications, and all kinds of knowledge that can assist your projects. You are also welcome to contact us directly for more specific solutions.
HighlightsGet a real taste of Creative Biolabs, one of the most professional custom service providers in the world. We are committed to providing highly customized comprehensive solutions with the best quality to advance your projects.
Highlights| Protein Name | Adhesion G protein-coupled receptor L1 |
| Gene Name | ADGRL1 |
| Uniprot | O94910 (Human); Q80TR1 (Mouse) |
| Synonym | CL1; LEC2; CIRL1; LPHN1; CIRL-1; calcium-independent alpha-latrotoxin receptor 1; latrophilin-1; lectomedin-2 |
| Background | ADGRL1, also known as Calcium-independent alpha-latrotoxin receptor 1 or Latrophilin-1 (LPHN1), is a protein encoded by the human ADGRL1 gene. As a member of the novel family of G protein-coupled receptors which previously thought to be brain-specific, ADGRL1 is characterized by an extended extracellular region with a variable number of protein domains coupled to a TM7 domain via a domain known as the GPCR-Autoproteolysis INducing (GAIN) domain. |
Creative Biolabs offers comprehensive range of membrane protein products empowers your unique research needs.
| CAT# | Product Name | Expression System | Protein Length | Solubilizing Agents |
| S01YF-1023-KX306 | NativeExtract™ Human ADGRL1 Membrane Protein (Full length, Super Nanodisc) | HEK293 cell | Full length | Native Nanodisc |
| MP0650X | MemDX™ Membrane Protein Human ADGRL1 (Adhesion G protein-coupled receptor L1) for Antibody Discovery | Wheat germ cell-free | Full length | N/A |
| Please for more products or customization | ||||
L***s: Creative Biolabs' ADGRL1 protein exhibits exceptional purity and correct post-translational modifications.
13/Aug/2023
S***ia: Timely turnaround and tailored purification protocols enabled seamless integration into our structural biology workflow.
27/Jan/2024
ADGRL1 Gene Therapy Development
We provide tailored solutions to meet your specific requirements. Please for more services.
AAV-Mediated Overexpression
Creative Biolabs offers AAV-mediated overexpression services. Adeno-associated virus (AAV) vectors engineered for selective transduction of dorsal root ganglia neurons enable localized ADGRL1 overexpression, a strategy validated in preclinical models of neuropathic pain. By suppressing hyperexcitability in nociceptive pathways, this approach restores physiological pain thresholds without systemic off-target effects. Creative Biolabs' expertise in designing tissue-specific promoters ensures optimal transgene expression in sensory neurons, a critical factor for therapeutic precision.
Epigenetic Silencing in Addiction Pathways
Creative Biolabs offers epigenetic silencing in addiction pathways services. Preclinical data demonstrate reduced cocaine-seeking behaviors in animal models through selective modulation of reward circuitry. This strategy circumvents permanent genomic edits while maintaining dose-dependent efficacy. Creative Biolabs' proprietary RNA optimization protocols enhance target specificity, minimizing off-site transcriptional interference.
Antisense Oligonucleotides (ASOs) for Metastatic Cancer
Creative Biolabs offers ASOs development services. Systemically delivered ASOs targeting ADGRL1 mRNA disrupt its interaction with integrin β1, effectively inhibiting tumor cell extravasation in models of triple-negative breast cancer. Lipid-nanoparticle formulations with blood-brain barrier-penetrating motifs are under evaluation for glioblastoma applications. Creative Biolabs' metabolomic profiling services can identify predictive biomarkers to stratify patients likely to benefit from this modality.
Creative Biolabs offers comprehensive and innovative services to drive the development of ADGRL1 cell therapy. Please for more services.
CAR Macrophages for Solid Tumors
Creative Biolabs offers CAR macrophages development services. ADGRL1-directed CAR macrophages engineered with hypoxia-responsive promoters exhibit enhanced tumor infiltration and phagocytic activity in pancreatic adenocarcinoma models. These cells secrete IL-12 in situ to remodel immunosuppressive microenvironments while degrading fibrotic stroma via MMP-9 co-expression. Creative Biolabs' ex vivo macrophage differentiation protocols ensure >90% target engagement efficiency, a prerequisite for clinical translation.
iPSC-Derived Oligodendrocytes
Creative Biolabs offers iPSC-derived oligodendrocyte development services. ADGRL1-knockout iPSCs differentiated into myelinating oligodendrocytes accelerate remyelination in demyelinating disorders. RNA sequencing confirms restored ADGRL1-mediated Wnt signaling, critical for axonal metabolic support. Creative Biolabs' gene-editing services enable scarless modification of patient-derived iPSCs, preserving genomic stability across >50 passages.
Autologous Tregs with ADGRL1 Co-Stimulation
Creative Biolabs offers autologous Tregs with ADGRL1 co-stimulation services. Engineering regulatory T cells (Tregs) to express membrane-bound ADGRL1 agonists enhances their immunosuppressive capacity in graft-versus-host disease models. This dual-signaling system amplifies CTLA-4 and PD-1 checkpoint activity while blocking dendritic cell maturation. Creative Biolabs' flow cytometry panels quantify ADGRL1 dimerization kinetics, enabling iterative optimization of co-stimulatory constructs.
The intricate biology of ADGRL1 demands solutions that balance target engagement precision with clinical scalability. Creative Biolabs' cross-platform capabilities—from AAV tropism engineering to functional iPSC banking—accelerate therapeutic validation across neurological, oncological, and immunologic indications. to discuss customized vector designs or schedule a portfolio review to benchmark your cell therapy candidates against industry-leading QC standards.
All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.
